Strontium Ranelate: A Review of its Use in the Treatment of Postmenopausal Osteoporosis

Drugs

Volumn 70, Issue 6, 2010, Pages 733-759

  Deeks, Emma D ^a   Dhillon, Sohita ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALUMINUM HYDROXIDE; BISPHOSPHONIC ACID DERIVATIVE; BIVALOS; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; ETIDRONIC ACID; IBANDRONIC ACID; MAGNESIUM HYDROXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; PROTAXOS; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ABDOMINAL PAIN; AMNESIA; AREA UNDER THE CURVE; ASIAN; BEDTIME DOSAGE; BONE DENSITY; BONE MINERALIZATION; BONE STRUCTURE; BONE TURNOVER; BRONCHUS HYPERREACTIVITY; CALCIUM BLOOD LEVEL; CLAVICLE FRACTURE; CLINICAL TRIAL; CONFUSION; CONSCIOUSNESS; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DERMATITIS; DIARRHEA; DRESS SYNDROME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; FOOD DRUG INTERACTION; HEADACHE; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; KYPHOSIS; LOOSE FECES; LUMBAR SPINE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL PAIN; NAUSEA; NONHUMAN; ORAL MUCOSAL DISEASE; OSSIFICATION; OSTEOARTHRITIS; OSTEOBLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PELVIS FRACTURE; PERIPHERAL EDEMA; POSTMARKETING SURVEILLANCE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; REVIEW; RIB FRACTURE; RISK FACTOR; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; STEVENS JOHNSON SYNDROME; TREATMENT DURATION; VERTEBRA FRACTURE; VOMITING; WRIST FRACTURE;

ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; FRACTURES, BONE; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; THIOPHENES; TREATMENT OUTCOME;

EID: 77951048379     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/10481900-000000000-00000     Document Type: Review

References (104)

1. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series [online]. Available from URL: http://whqlibdoc.who.int/trs/WHO-TRS-843. pdf [Accessed 2009 Oct 23]
2. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis [online]. Available from URL: http://www.nof.org/ professionals/NOF- Clinicians-Guide.pdf [Accessed 2009 Oct 23]
3. International Osteoporosis Foundation. Facts and statistics about osteoporosis and its impact [online]. Available from URL: http://www. iofbonehealth.org/facts-and-sta tistics.html#factsheet-category-22 [Accessed 2009 Oct 23]
4. Girotra M, Rubin MR, Bilezikian JP. Anabolic agents for osteoporosis: what is their likely place in therapy? Treat Endocrinol 2006; 5 (6): 347-358
5. Reginster JY, Deroisy R, Jupsin I. Strontium ranelate: a new paradigm in the treatment of osteoporosis. Drugs Today (Barc) 2003 Feb; 39 (2): 89-101
6. Marie PJ, Ammann P, Boivin G, et al. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001 Sep; 69 (3): 121-129
7. Marie PJ. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation. Curr Opin Rheumatol 2006 Jun; 18 Suppl. 1: S11-5
8. Marie PJ. Strontium ranelate: new insights into its dual mode of action. Bone 2007; 40 (5 Suppl. 1): S5-8
9. Fonseca JE. Rebalancing bone turnover in favour of formation with strontium ranelate: implications for bone strength. Rheumatology (Oxford) 2008 Jul; 47 (Suppl. 4): iv17-9
10. European Medicines Agency. Protelos 2g granules for oral suspension: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/protelos/emea-combined-h560en. pdf [Accessed 2009 Oct 20]
11. European Medicines Agency. Protelos: scientific discussion [online]. Available from URL: http://www.emea.europa. eu/humandocs/PDFs/EPAR/protelos/ 121604en6.pdf [Accessed 2009 Oct 12]
12. Canalis E, Hott M, Deloffre P, et al. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996 Jun; 18 (6): 517-523
13. Bonnelye E, Chabadel A, Saltel F, et al. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 2008 Jan; 42 (1): 129-138
14. Atkins GJ, Welldon KJ, Halbout P, et al. Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprote-gerin response. Osteoporos Int 2009 Apr; 20 (4): 653-664
15. Baron R, Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 2002 Aug 16; 450 (1): 11-17
16. Takahashi N, Sasaki T, Tsouderos Y, et al. S 12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 2003 Jun; 18 (6): 1082-1087
17. Delannoy P, Bazot D, Marie PJ. Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Metabolism 2002 Jul; 51 (7): 906-911
18. Hott M, Deloffre P, Tsouderos Y, et al. S12911-2 reduces bone loss induced by short-term immobilization in rats. Bone 2003 Jul; 33 (1): 115-123
19. Buehler J, Chappuis P, Saffar JL, et al. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 2001 Aug; 29 (2): 176-179
20. Marie PJ, Hott M, Modrowski D, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993 May; 8 (5): 607-615
21. Brennan TC, Rybchyn MS, Green W, et al. Osteoblasts play key roles in the mechanisms of action of strontium ranelate. Br J Pharmacol 2009 Aug; 157 (7): 1291-1300
22. Coulombe J, Faure H, Robin B, et al. In vitro effects of strontium ranelate on the extracellular calcium-sensing receptor. Biochem Biophys Res Commun 2004 Oct 29; 323 (4): 1184-1190
23. Chattopadhyay N, Quinn SJ, Kifor O, et al. The calciumsensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation. Biochem Pharmacol 2007 Aug 1; 74 (3): 438-447
24. Zhu LL, Zaidi S, Peng Y, et al. Induction of a program gene expression during osteoblast differentiation with strontium ranelate. Biochem Biophys Res Commun 2007 Apr 6; 355 (2): 307-311
25. Caverzasio J. Strontium ranelate promotes osteoblastic cell replication through at least two different mechanisms. Bone 2008 Jun; 42 (6): 1131-1136
26. Hurtel-Lemaire AS, Mentaverri R, Caudrillier A, et al. The calcium-sensing receptor is involved in strontium rane-late-induced osteoclast apoptosis: new insights into the associated signaling pathways. J Biol Chem 2009 Jan 2; 284 (1): 575-584
27. Fromigue O, Hay E, Barbara A, et al. Calcium sensing receptor-dependent and-independent activation of osteo-blast replication and survival by strontium ranelate. J Cell Mol Med. Epub 2009 Jan 28
28. Ammann P, Shen V, Robin B, et al. Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats. J Bone Miner Res 2004 Dec; 19 (12): 2012-2020
29. Ammann P, Badoud I, Barraud S, et al. Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. J Bone Miner Res 2007 Sep; 22 (9): 1419-1425
30. Bain SD, Jerome C, Shen V, et al. Strontium ranelate improves bone strength in ovariectomized rat by positively influencing bone resistance determinants. Osteoporos Int 2009 Aug; 20 (8): 1417-1428
31. Arlot ME, Jiang Y, Genant HK, et al. Histomorphometric and mCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 2008 Feb; 23 (2): 215-222
32. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmen-opausal vertebral osteoporosis-a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002 May; 87 (5): 2060-2066
33. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004 Jan 29; 350 (5): 459-468 (Pubitemid 38133766)
34. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: TReatment Of Peripheral OSteoporosis (TROPOS) study. J Clin En-docrinol Metab 2005 May; 90 (5): 2816-2822
35. Recker RR, Marin F, Ish-Shalom S, et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 2009 Aug; 24 (8): 1358-1368
36. Anastasilakis AD, Polyzos SA, Avramidis A, et al. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide. Horm Metab Res 2009 Jul; 41 (7): 559-562
37. Middleton ET, Steel SA, Aye M, et al. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate. J Bone Miner Res 2009 Dec 11; 25 (3): 455-462
38. Li YF, Luo E, Feng G, et al. Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats. Osteoporos Int. Epub 2009 Dec
39. Habermann B, Kafchitsas K, Olender G, et al. Strontium ranelate enhances callus strength more than PTH 1-34 in an osteoporotic rat model of fracture healing. Calcif Tissue Int 2010 Jan; 86 (1): 82-89
40. Farlay D, Boivin G, Panczer G, et al. Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone. J Bone Miner Res 2005 Sep; 20 (9): 1569-1578
41. Boivin G, Farlay D, Khebbab MT, et al. In osteoporotic women treated with strontium ranelate, strontium is located in bone formed during treatment with a maintained degree of mineralization. Osteoporos Int 2010 Apr; 21 (4): 667-677
42. Meunier PJ, Roux C, Ortolani S, et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 2009 Oct; 20 (10): 1663-1673
43. Hwang JS, Chen JF, Yang TS, et al. The effects of strontium ranelate in Asian women with postmenopausal osteoporosis [published erratum appears in Calcif Tissue Int 2009 Apr; 84 (4): 334]. Calcif Tissue Int 2008 Nov; 83 (5): 308-314
44. Alexandersen P, Karsdal MA, Qvist P, et al. Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. Bone 2007 Jan; 40 (1): 218-222
45. Anastasilakis AD, Goulis DG, Polyzos SA, et al. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teripara-tide: a randomized controlled trial. Clin Endocrinol (Oxf) 2009 Apr; 70 (4): 522-526
46. Bruyere O, Collette J, Rizzoli R, et al. Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ra-nelate for 3 years. Osteoporos Int. Epub 2009 Oct
47. Halil M, Cankurtaran M, Yavuz BB, et al. Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis. Ann Pharmacother 2007 Jan; 41 (1): 41-45
48. Reginster JY, Bruyere O, Sawicki A, et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone 2009 Dec; 45 (6): 1059-1064
49. Liu JM, Wai-Chee Kung A, Pheng CS, et al. Efficacy and safety of 2g/day of strontium ranelate in Asian women with postmenopausal osteoporosis. Bone 2009 Sep; 45 (3): 460-465
50. Ringe JD, Doherty JG. Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatol Int. Epub 2009 Dec
51. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008 Jun; 58 (6): 1687-1695
52. Marquis P, Roux C, de la Loge C, et al. Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteo-poros Int 2008 Apr; 19 (4): 503-510
53. Bruyere O, Roux C, Detilleux J, et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 2007 Aug; 92 (8): 3076-3081
54. Bruyere O, Roux C, Badurski J, et al. Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium rane-late. Curr Med Res Opin 2007 Dec; 23 (12): 3041-3045
55. Roux C, Reginster JY, Fechtenbaum J, et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 2006 Apr; 21 (4): 536-542
56. Collette J, Bruyere O, Kaufman JM, et al. Vertebral antifracture efficacy of strontium ranelate according to pre-treatment bone turnover. Osteoporos Int 2010 Feb; 21 (2): 233-241
57. Seeman E, Vellas B, Benhamou C, et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 2006 Jul; 21 (7): 1113-1120
58. Seeman E, Boonen S, Borgstrom F, et al. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Bone 2010 Apr; 46 (4): 1038-1042
59. Roux C, Fechtenbaum J, Kolta S, et al. Strontium ranelate reduces the risk of vertebral fracture in young postmeno-pausal women with severe osteoporosis. Ann Rheum Dis 2008 Dec; 67 (12): 1736-1738
60. Bruyere O, Delferriere D, Roux C, et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 2008 Mar; 67 (3): 335-339
61. Roux C, Fechtenbaum J, Kolta S, et al. Prospective assessment of thoracic kyphosis in postmenopausal women with osteoporosis. J Bone Miner Res. Epub 2009 Jul 13
62. Seeman E, Devogelaer JP, Lorenc R, et al. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res 2008 Mar; 23 (3): 433-438
63. Grosso A, Douglas I, Hingorani A, et al. Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 2008 Nov; 66 (5): 689-694
64. Breart G, Cooper C, Meyer O, et al. Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK and General Practice Research Database. Osteo-poros Int. Epub 2009 Oct 6
65. Borgstrom F, Jonsson B, Strom O, et al. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int 2006 Dec; 17 (12): 1781-1793
66. Borgstrom F, Strom O, Coelho J, et al. The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int 2010 Feb; 21 (2): 339-349
67. Hiligsmann M, Bruyere O, Reginster JY. Cost-utility of long-term strontium ranelate treatment for postmeno-pausal osteoporotic women. Osteoporos Int 2010 Jan; 21 (1): 157-165
68. Hiligsmann M, Bruyere O, Reginster JY. Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years. Bone 2010 Feb; 46 (2): 440-446
69. O'Donnell S, Cranney A, Wells GA, et al. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev [CD005326]
70. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev [CD004523]
71. Scottish Intercollegiate Guidelines Network. Management of osteoporosis: a national clinical guideline [online]. Available from URL: http://www.sign.ac. uk [Accessed 2009 Oct 23]
72. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women [published erratum appears in Osteoporos Int 2008 Jul; 19 (7): 1103-4]. Osteoporos Int 2008 Apr; 19 (4): 399-428
73. Raisz LG. Pathogenesisof osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005 Dec; 115 (12): 3318-3325
74. Deeks ED, Perry CM. Zoledronic acid: a review of its use in the treatment of osteoporosis. Drugs Aging 2008; 25 (11): 963-986
75. European Medicines Agency. Aclasta: summary of product characteristics [online]. Available from URL: http://www. emea.europa.eu/humandocs/PDFs/EPAR/ aclasta/emea-co mbined-h595en.pdf [Accessed 2009 Nov 4]
76. Miller PD. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Ther 2005 Apr; 27 (4): 361-376
77. European Medicines Agency. Bonviva: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/ Bonviva/emea-combined-h501en.pdf [Accessed 2010 Mar 24]
78. European Medicines Agency. Fosavance: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/ Fosavance/emea-combined-h619en.pdf [Accessed 2010 Mar 24]
79. European Medicines Agency. Evista: summary of product characteristics [online]. Available from URL: http://www. emea.europa.eu/humandocs/PDFs/EPAR/ Evista/H-184-PI-en.pdf [Accessed 2009 Nov 4]
80. European Medicines Agency. Forsteo: summary of product characteristics [online]. Available from URL: http://www. emea.europa.eu/humandocs/PDFs/EPAR/ forsteo/emea-co mbined-h425en.pdf [Accessed 2009 Nov 4]
81. European Medicines Agency. Preotact: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ preotact/H-659-PI-en.pdf [Accessed 2009 Nov 4]
82. Merck Sharp and Dohme Limited. Fosamax: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2009 Nov 4]
83. Gold DT, Alexander IM, Ettinger MP. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy. Ann Pharmacother 2006 Jun; 40 (6): 1143-1150
84. Procter and Gamble Pharmaceuticals UK Limited. Actonel once a week 35 mg film coated tablets: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2010 Mar 24]
85. Procter and Gamble Pharmaceuticals UK Limited. Actonel 5mg film coated tablets: summary of product characteristics [online]. Available from URL: http://emc. medicines.org.uk [Accessed 2010 Mar 24]
86. Boonen S, Body JJ, Boutsen Y, et al. Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 2005 Mar; 16 (3) 239-254
87. Agence française de securite sanitaire des produits de sante. Traitement medicamenteux de l'osteoporose post-meno-pausique: recommandations (actualisation 2006) [online]. Available from URL: http://www.afssaps.fr/var/ afssaps- site/storage/original/application/6c7b18b541509aa9f4994 84099d5f8e8.pdf [Accessed 2010 Jan 19]
88. Macas JG, Gay NG, Alonso CG, et al. Clinical practice guidelines for postmenopausal, esteroid and male osteoporosis: Spanish Society for Bone and Mineral Research. Rev Clin Esp 2008 May; 208 Suppl. 1, 1-24
89. National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/TA160guidance.pdf [Accessed 2009 Oct 23]
90. National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women [online]. Available from URL: http://www.nice. org.uk/nicemedia/pdf/ TA161guidanceword.pdf [Accessed 2009 Oct 23]
91. Rizzoli R, Bruyere O, Cannata-Andia JB, et al. Management of osteoporosis in the elderly. Curr Med Res Opin 2009 Oct; 25 (10) 2373-2387
92. Papaioannou A, Kennedy CC, Dolovich L, et al. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 2007; 24 (1): 37-55
93. Cole Z, Dennison E, Cooper C. Update on the treatment of post-menopausal osteoporosis. Br Med Bull 2008; 86: 129-143
94. Boonen S, Dejaeger E, Vanderschueren D, et al. Osteoporosis and osteoporotic fracture occurrence and prevention in the elderly: a geriatric perspective. Best Pract Res Clin Endocrinol Metab 2008 Oct; 22 (5): 765-785
95. Inderjeeth CA, Foo ACH, Lai MMY, et al. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence. Bone 2009 May; 44 (5): 744-751
96. Kendler DL, Adachi JD, Josse RG, et al. Monitoring strontium ranelate therapy in patients with osteoporosis. Osteoporos Int 2009 Jul; 20 (7): 1101-1106
97. Barenholdt O, Kolthoff N, Nielsen SP. Effect of long-term treatment with strontium ranelate on bone strontium content. Bone 2009 Aug; 45 (2): 200-206
98. Goldstein SR, Duvernoy CS, Calaf J, et al. Raloxifene use in clinical practice: efficacy and safety. Menopause 2009 Mar-Apr; 16 (2): 413-421
99. Musette P, Brandi ML, Cacoub P, et al. Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Os-teoporos Int 2010 May; 21 (5): 723-732
100. European Medicines Agency. EMEA recommends changes in the product information for Protelos/Osseor due to the risk of severe hypersensitivity reactions [media release]. Available from URL: http://www.emea.europa.eu/human docs/PDFs/EPAR/protelos/PressRelease-Protelos-41745 807en.pdf [Accessed 2009 Sep 8]
101. Silverman SL, Minshall ME, Shen W, et al. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis. Arthritis Rheum 2001 Nov; 44 (11): 2611-2619
102. Warriner AH, Curtis JR. Adherence to osteoporosis treatments: room for improvement. Curr Opin Rheuma-tol 2009 Jul; 21 (4): 356-362
103. Rabenda V, Reginster JY. Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteo-porotic fractures. Osteoporos Int. Epub 2010 Jan
104. Richards JB, Cherkas LF, Spector TD. An analysis of which anti-osteoporosis therapeutic regimen would improve compliance in a population of elderly adults. Curr Med Res Opin 2007 Feb; 23 (2): 293-9